Insulet Corporation (PODD)
| Market Cap | 20.82B |
| Revenue (ttm) | 995.60M |
| Net Income (ttm) | -30.50M |
| Shares Out | 66.70M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | 192.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161,596 |
| Open | 299.54 |
| Previous Close | 298.69 |
| Day's Range | 298.29 - 303.59 |
| 52-Week Range | 214.93 - 309.99 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 291.88 (-3.8%) |
| Est. Earnings Date | Nov 4, 2021 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is...
Financial Performance
In 2020, Insulet's revenue was $904.40 million, an increase of 22.51% compared to the previous year's $738.20 million. Earnings were $6.80 million, a decrease of -41.38%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for Insulet stock is "Buy." The 12-month stock price forecast is 291.88, which is a decrease of -3.78% from the latest price.
News
Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced tha...
Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use
Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System. Omnipod 5 is a tubeless, wearable system that continuously a...
Insulet's Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented posit...
Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pla...
Here's Why You Should Retain Insulet (PODD) Stock for Now
Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).
5 Top Stocks for September
Our analysts give you five picks you can add to your portfolio today.
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management wi...
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
The FDA has approved the use of Eli Lilly And Co's (NYSE:LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ:PODD) insulin management systems. Lyumjev, approved ...
Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced FDA cleara...
Insulet Introduces Omnipod DASH® System at Australasian Diabetes Congress
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented the...
Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat
Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Insulet (PODD) Q2 Earnings Lag Estimates
Insulet (PODD) delivered earnings and revenue surprises of -16.67% and 2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced fin...
3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain
Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.
Earnings Preview: Insulet (PODD) Q2 Earnings Expected to Decline
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management wi...
Insulet to Announce Second Quarter 2021 Financial Results on August 5, 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pla...
Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5
Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.
Insulet's Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifes...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pro...
Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its...
Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat
Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.